FDA Clears First-Ever IND for Peeling Skin Syndrome, Quoin to Start Phase 2
QNRX sits 43% above its 52-week low of $3.25 on light trading volume (0.2× avg).
Summary
Quoin Pharmaceuticals received FDA clearance for its IND application for QRX003 in Peeling Skin Syndrome (PSS), a rare disease with no approved treatments. This is the first IND ever submitted to the FDA for PSS, and clearance enables a Phase 2 study enrolling 6-8 pediatric and adult patients in the US and Europe, starting in H2 2026. The FDA raised no safety concerns on study design or dosing duration, a positive signal for the broader QRX003 program. This follows recent momentum: QRX003 previously showed clinically meaningful improvements in an ongoing pediatric study, and the company secured Orphan Drug Designation in Japan for Netherton Syndrome in June. With a market cap under $10M, this regulatory milestone materially de-risks the pipeline and expands the addressable rare-disease opportunity. Next catalyst: alignment with FDA on the Phase 3 Netherton Syndrome study, also expected H2 2026.
At the time of this announcement, QNRX was trading at $4.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $3.25 to $41.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.